by Chloe Flower, Mewburn Ellis
Robotics and AI are rapidly reshaping surgery. From robot assisted systems to AI driven guidance and connected surgical platforms, surgeons now operate with levels of precision and insight that were unthinkable a decade ago. These technologies promise better outcomes and faster recovery, but clinical impact alone does not determine commercial success.
In today’s medtech landscape, intellectual property (IP) strategy is not a legal afterthought. It is a core business tool.
For surgical innovators understanding how patents work commercially is increasingly as important as understanding how the technology works clinically.
Patents as Business Assets, Not Just Legal Rights
In medtech, patents do far more than prevent copying. They act as commercial signals and transactional assets.
Investors, partners and acquirers rarely ask whether a technology is clever, they ask whether it is defensible. A well structured patent portfolio helps answer that question. Even at an early stage, a patent pending position can unlock investor conversations, support valuations, and enable strategic partnerships. In acquisition scenarios, IP is often the primary asset being acquired.
Crucially, patent strategy should align with business milestones. Filing ahead of key disclosures, funding rounds or clinical collaborations protects value and avoids accidental loss of rights. For many early stage companies, the goal is not maximal coverage on day one, but credible, focused protection that supports fundraising and commercial traction.
Why AI Patents Are Commercially Different from Device Patents
As surgery becomes more software driven, the commercial role of patents changes.
Traditional surgical devices are typically tangible, mechanical innovations. Patents in this space often map directly onto physical products and can be relatively straightforward to enforce. They tend to support long product lifecycles and act as durable market barriers.
AI enabled surgical technologies introduce different dynamics:
• Intangible innovation: Much of the value lies in algorithms, data processing and system integration rather than hardware alone. These can be harder to define in a patent and sometimes face stricter scrutiny from patent offices. However, if an algorithm delivers a technical benefit – e.g. real-time image analysis improving surgical accuracy – it can be patentable: teams are now patenting not just hardware, but how smart software is trained and integrated into surgical tools. A key example is training-data innovations: adapting robotic systems to record and use surgical data for AI training might itself be a protectable invention.
• Platform value over component value: AI patents often protect how a system functions or improves outcomes, rather than a discrete component. Commercially, this supports licensing, partnerships and platform expansion rather than single product exclusivity.
• Crowded vs Open Space: Robotic surgery hardware has been in development for 20+ years, resulting in a crowded patent space. Conversely, AI-driven surgical methods are newer – there’s more “open space” for first-time patents in how AI guides procedures or how connected surgical networks operate. This means surgical innovators have a chance to carve out fresh IP in the AI domain, even where hardware patents already exist. Many companies are doing exactly that, bridging traditional devices and digital tech with patents on integrated systems (e.g. a robot+software combo). The overall trend is a blurring of lines between device patents and software patents as products become a mix of both.
• Speed of evolution: AI systems evolve rapidly. As a result, patents often function as strategic stakes in the ground, supported by ongoing filings as the technology develops, rather than static, once and done protection.
• Patents plus trade secrets: In AI, the most commercially sensitive assets - training data, model tuning, workflow know how - are often better protected as trade secrets. The strongest strategies combine patents (to signal value and deter competitors) with confidentiality (to protect what cannot be reverse engineered).
Investors increasingly expect this blended approach. What matters is not whether everything is patented, but whether there is a coherent, commercially rational IP strategy.
Commercial IP Strategy for Surgical Innovators
For companies operating at the intersection of devices, robotics and AI, IP portfolios typically need to do several jobs at once:
• Protect core hardware or system architecture that competitors can physically copy
• Capture AI enabled functionality that delivers clinical advantage
• Support fundraising and partnerships with credible, well drafted filings
• Leave room for future product evolution and regulatory timelines
This often means building layered portfolios - foundational patents early, followed by targeted filings as products mature. The aim is not legal complexity, but commercial optionality.
Freedom to Operate: The Commercial Reality Check
Even the most groundbreaking surgical invention can be stopped in its tracks by a competitor’s patent. That’s where Freedom to Operate (FTO) comes in. FTO means ensuring that you have the right to make and use your product without infringing existing patents. Many clinicians-turned-innovators are surprised to learn that having your own patent does not guarantee FTO. In other words, a patent gives you the right to exclude others from your invention, but it doesn’t automatically let you use all the underlying technology if parts of it are patented by someone else. For example, you might patent a clever AI module for surgical navigation, but if the overall robotic platform uses techniques covered by another company’s patents, you could still be blocked from the market.
In fields like surgical robotics and AI, patent activity is intense and overlapping – a single product might implicate dozens of prior patents. An early FTO analysis helps uncover potential IP issues while there’s still time to pivot. It is far better to discover a blocking patent during R&D than after building a device or raising funding. With robotics and AI products, core components such as imaging modules, algorithms, or connectivity features may be patented by others, and knowing that early allows you to design around them or seek licences proactively.
There are a few common misconceptions to dispel:
• “We’ll handle IP once the product is ready.” In reality, IP strategy, including FTO, should start at concept and prototyping stage, before public disclosures or regulatory filings. Early checks make it easier to tweak designs and avoid major headaches later.
• “Our startup is small; big companies won’t notice us.” In med-tech, larger players do monitor new entrants, especially in key growth areas like robotic surgery. Being small doesn’t immunize you from IP challenges. The good news is investors and partners appreciate startups who de-risk IP early: doing your FTO homework signals professionalism and saves them from surprises.
• “We have a patent pending, so we’re safe.” Remember, your patent protects your invention, but doesn’t clear others’ rights. You need both a strong patent and freedom to operate to safely commercialize. One analogy: patents are shields for your idea; FTO is checking for other people’s swords that might still harm you.
Importantly, FTO is not a one off exercise - it should evolve alongside the product. Treat FTO as an ongoing process: as your device evolves or new patents are published, update your FTO understanding. It’s much like how a surgeon monitors vital signs throughout a procedure to avoid complications.
Practical Takeaways for Surgical Innovators
- Integrate IP into your innovation process from day one. Early patent filings can help open investor conversations and partnerships, while early FTO analysis helps you avoid infringing others’ patents when it is easiest to adjust course.
- Know your landscape – both technical and IP. Robotics, AI, imaging, and connected devices are converging into a complex ecosystem. By exploring patents in adjacent fields, you might find inspiration or white spaces to innovate in – and you’ll certainly get a sense of which big players hold key patents in your area. For a surgeon founder, this kind of IP awareness is as important as scouting the clinical or market landscape.
- Tailor your patent strategy to your tech. If you’re developing a novel instrument or hardware device, a straightforward patent on the mechanical innovation is the starting point. If your value lies in AI or software, think about patenting the integrated system – e.g. how your AI ties into a surgical workflow or improves an outcome – rather than abstract algorithms. Ensure your patents are written to withstand scrutiny (med-tech patents are frequently challenged by competitors, so clarity and solid data support are vital). And remember the bigger picture: not everything can be patented (e.g. pure surgical methods or discoveries might be exempt in some regions), so consider trade secrets or collaborations for those aspects.
- Don’t fear FTO – use it as a guide. Freedom to Operate is not about avoiding innovation; it is about smart navigation. A thorough FTO search can reveal patent “red zones” where others have strong rights and also identify expired patents or open technology that you are free to use.
In conclusion, the surgical innovation boom – with robotics, AI, and connected platforms – offers tremendous opportunities to improve patient care and outcomes. By pairing cutting-edge technology with a clear IP strategy, surgeon-led startups and med-tech companies can bring new solutions to market with greater confidence. The key is to think ahead: in an era where technology and IP are deeply intertwined, the winners will be those who innovate boldly and navigate smartly.
